Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone

(2019) Krister Bamberg et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

(2018) Fredrik Erlandsson et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists

(2018) Marco Trevisan et al.   EUROPEAN JOURNAL OF HEART FAILURE

Pharmacological treatments for heart failure with preserved ejection fraction—a systematic review and indirect comparison

(2018) Kwadwo Osei Bonsu et al.   HEART FAILURE REVIEWS

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion

(2018) Krister Bamberg et al.   PLoS One

Mineralocorticoid Receptor and Cardiovascular Disease

(2018) Mathieu Buonafine et al.   AMERICAN JOURNAL OF HYPERTENSION

Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF

(2017) João Pedro Ferreira et al.   EUROPEAN JOURNAL OF HEART FAILURE

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis

(2017) Greg H. Tesch et al.   Frontiers in Pharmacology

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation

(2016) Jozine M. ter Maaten et al.   EUROPEAN JOURNAL OF HEART FAILURE

Hyperkalemia in Heart Failure

(2016) Chaudhry M.S. Sarwar et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis

(2016) Nathan R. Hill et al.   PLoS One

Evidence for a gastrointestinal–renal kaliuretic signaling axis in humans

(2015) Richard A. Preston et al.   KIDNEY INTERNATIONAL

Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort

(2015) Sascha Abbas et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Spironolactone for Heart Failure with Preserved Ejection Fraction

(2014) Bertram Pitt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidemiology of Heart Failure

(2013) Véronique L. Roger   CIRCULATION RESEARCH

Aldosterone and cardiovascular disease: the heart of the matter

(2012) B. Julie He et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

A validated liquid chromatography–tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma

(2011) Nico C. van de Merbel et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

(2011) Rena J Eudy et al.   Journal of Translational Medicine

Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease

(2011) Jean-Philippe Bertocchio et al.   KIDNEY INTERNATIONAL

Aldosterone and inflammation

(2011) Kimberly C Gilbert et al.   Current Opinion in Endocrinology Diabetes and Obesity

Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

(2008) Michael Gekle et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY